

Agenda Released for 3D Cell Culture 2018 Featuring Novartis Institutes for Biomedical Research, GSK and Roche

SMi Group announce the return of 3D Cell Culture following a sell-out launch event in 2017

LONDON, ENGLAND, UNITED KINGDOM, September 26, 2017 /EINPresswire.com/ -- Building on the success of the launch event, SMi Group is delighted to announce the return of <u>3D Cell Culture</u> taking place next February in London, UK. The field of 3D Cell Culture is rapidly growing with incredible potential for industrial application and a widespread reach that can be seen across many different areas, such as 3D bioprinting and microfluidics. With an aim at strengthening commercial success, the agenda for the 2nd annual event will explore these overlapping areas to combine pioneering breakthroughs with scientific research.



The release of the 2nd annual conference follows positive feedback from the industry such as:

"Very good presentations and a few outstanding ones... I made some useful contacts" - ASTERAND BIOSCIENCE; "The conference was wonderfully organised" – NOVARTIS; and "Good start, love to see the event occur again" - THERMO FISHER SCIENTIFIC

٢٢

Very good presentations and a few outstanding ones... I made some useful contacts -Previous attendee testimonial" ASTERAND BIOSCIENCE Programme highlights will include:

Talks on uncovering the biology of human neurodevelopment diseases in 3D by merging technologies in CRISPR editing and single cell sequencing Case studies on the Zika virus and tuberous sclerosis New approaches to predictive substance testing through informed insight into multi-organ-chip technology Strategic guidance for optimising the placement of cells in

printing

Key developments in the overlap of 3D bioprinting and 3D cell culturing

Some of the notable speakers for 2018 will include:

Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience Stefan Przyborski, Scientific Founder, ReInnervate Limited Ricardo Baptista, Lead Scientist Process Development, Cell and Gene Therapy Catapult Nicholas Leslie, Tumour Biologist, Heriot-Watt University Suwan Jaysinghe, Professor of Bioengineering, University College London Max Salick, Postdoctoral Researcher, Novartis Institutes for Biomedical Research Patrick Kugelmeier, Director of Science, Kugelmeiers Vitor Santo, Senior Scientist, Immunocore Christopher Schofield, Investigator, GSK David Pan, Programme Manager (Regenerative Medicine), UK Regenerative Medicine Platform Reyk Horland, Head of Business Development, TissUse GmbH

<u>3D Cell Culture 2018</u> will take place on 21st and 22nd February at the Holiday Inn Kensington Forum in Central London, UK.

For those looking to attend, there is currently a £400 early bird saving online which expires on 31st October

Further information including a full speaker line-up and detailed agenda is available online at <u>www.3D-cellculture.com</u>

---end----

Contact Information:

For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smionline.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri SMi Group 2078276000 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.